In respect of the anti-inflammatory [123] and anti-aggregant [124] properties of ACE2, current phase 2 clinical trials might bring promising results in regard to recombinant human ACE2 as a potential treatment of ARDS [125] and severe cases of COVID-19 [126]. Here, ACE2 is linked to acute respiratory distress syndrome.